CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25593342.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2491.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- ErbB Receptors